Developer docs
API playgroundTry for free, no card

Search company profiles

Ketim Therapeutics Pty Ltd

Full company profile

uuid02lr7ow

Namestring
Ketim Therapeutics Pty Ltd
Legal namestring
Ketim Therapeutics Pty Ltd
Websiteurl
ketim.com.au
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Ketim Therapeutics Pty Ltd (doing business as Ketim Technologies) is an Australian, Brisbane-based biotechnology company founded in 2024 that is developing what it claims to be the world's first protein blood-based objective clinical test for postpartum depression (PPD). The core product is a predictive blood assay built on a proprietary four-protein biomarker signature reported to deliver up to 94% sensitivity and specificity (AUC) when performed at 24 weeks gestation — before symptoms manifest — derived from screening over 5,400 candidate proteins against multimodal patient data. The assay is paired with an AI/ML-enabled analytical pipeline and a proprietary database integrating biomarker, clinical, and patient-reported data, intended to support biomarker discovery, drug discovery, and clinical-trial optimization for psychiatric conditions more broadly. The company has filed an international PCT patent application covering the biomarker technology (Feb 2026) and is generating validation data through strategic partnerships with Mater Research (Queensland Family Cohort), the Australian Genome Research Facility (proteomics via Olink platforms), the Thompson Institute at the University of the Sunshine Coast, and provisional access to the ORIGINS Birth Cohort Biobank. A Swedish dried-blood-spot partnership with Capitainer extends sample-collection flexibility for the test.

The company is pre-revenue and pre-commercialization: no pricing is publicly disclosed, the product is not yet approved by the FDA, TGA, or equivalent regulators, and the trials.ketim.com.au portal exists to enroll validation cohorts rather than to deliver paid services. Planned revenue streams include clinical laboratory testing services and potential kit sales for the blood-based diagnostic, biomarker database licensing to pharmaceutical companies, and biomarker-driven clinical trial optimization services. Planned customer segments are healthcare providers and pregnant women for the diagnostic test, and pharmaceutical companies for the database and trial-optimization offerings. As of late 2025 / early 2026 the company had closed an oversubscribed AUD $1.2 million pre-seed round at a $3.7 million post-money valuation, accumulated roughly AUD $1.275 million in combined equity and non-dilutive grant funding (including a AUD $75K Advance Queensland Ignite Spark Grant), and was pursuing competitive grants reportedly aggregating to AUD $4.5 million for biomarker validation and regulatory progression. Go-to-market is enterprise/clinical field-sales led: direct engagement with clinicians, partnerships with maternity hospitals for cohort and biobank access, participation in accelerator programs (BEDA MedTech Global Accelerator, AusBiotech IGP), and investor and life-sciences conference presence (RESI JPM 2026, AusMedTech 2025). The operating geography is anchored in Australia with explicit strategic interest in Singapore/Southeast Asia and the United States.

Short descriptiontext

Ketim Therapeutics (Ketim Technologies) is a Brisbane, Australia-based biotechnology company developing the world's first protein blood-based predictive test for postpartum depression, paired with an AI/ML-enabled multimodal biomarker database for maternal mental-health diagnostics and pharmaceutical drug-discovery applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBrisbane, Australia
HQ citystring
Brisbane
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomarker diagnostics, postpartum depression screening, precision psychiatry, blood-based biomarker testing, maternal mental health
Industry3 codes
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Maternal Mental Health Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Blood-Based Diagnostic Test Sales
TypeHardware Sales
Description

The company is developing and plans to commercialize a protein blood-based diagnostic test for postpartum depression prediction, expected to generate revenue through clinical laboratory testing services and potentially kit sales.

ketim.com.au
2Biomarker Database Licensing
TypeData Monetisation
Description

Licensing of proprietary biomarker database to pharmaceutical companies for drug discovery and development purposes.

ketim.com.au
3Clinical Trial Optimization Services
TypeProfessional Services
Description

Providing biomarker-driven insights to pharmaceutical companies for clinical trial design and patient stratification.

ketim.com.au
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ketim Technologies is commercializing a proprietary protein blood-based diagnostic test that predicts postpartum depression risk at 24 weeks gestation using a four-protein biomarker signature with up to 94% sensitivity and specificity (AUC), before symptoms occur. The company is also building an AI/ML-enabled proprietary multimodal database that integrates biomarker, clinical, and health data to support biomarker discovery, drug discovery, and clinical trial optimization for perinatal mental health.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 94% sensitivity and specificity (AUC) for PPD prediction at 24 weeks gestation
+2 more records
Product overview1 text field

Ketim Technologies is developing the world's first protein blood-based objective clinical test for postpartum depression (PPD) using a proprietary four-protein biomarker signature achieving up to 94% sensitivity and specificity. The core offering consists of a predictive blood test that can identify PPD risk at 24 weeks gestation, before symptoms manifest. This is supported by an AI-driven proprietary database that integrates multimodal patient data (molecular, clinical, and health information) to power biomarker discovery and drug discovery for mental health conditions.

Product and service2 records
1Postpartum Depression (PPD) Blood Test
CategoryMaternal Mental Health Diagnostics
Description

A novel protein blood-based objective clinical test that predicts postpartum depression (PPD) risk using a proprietary four-protein biomarker signature with up to 94% sensitivity and specificity (AUC), performed at 24 weeks gestation—months before symptoms occur. Intended for healthcare providers, obstetricians, and antenatal care clinics to enable early screening and personalized intervention for pregnant women.

2AI-Driven Proprietary Biomarker and Drug Discovery Database
CategoryDrug Discovery / Clinical Trial Optimization Platform
Description

A proprietary biomarker and drug discovery database that integrates multimodal patient data including molecular, clinical, and health information, powered by advanced AI and machine learning. Designed to uncover novel biomarkers, accelerate drug development, and optimize clinical trial design for pharmaceutical and biotech partners in mental health (starting with PPD).

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership leveraging the Queensland Family Cohort (QFC) study for predictive biomarker research for perinatal depression. The collaboration provides access to longitudinal datasets encompassing genetic, environmental, and health factors for biomarker discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ongoing collaboration advancing biomarker discovery and translational pipeline. AGRF provides proteomics expertise and genomic technologies supporting Ketim's biomarker validation work using Olink proteomics platforms.

3Thompson Institute at University of the Sunshine Coast
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration to evaluate the specificity of Ketim's postpartum depression biomarker signature through independent validation studies.

ketim.com.au
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Provisional approval to access the ORIGINS Birth Cohort Biobank for independent validation of postpartum depression biomarker panel. Enables validation studies in an independent birth cohort.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Selected for Year 4 Cohort of BEDA's MedTech Global Accelerator Program supporting global expansion strategy and commercialization pathways.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AusBiotech-delivered Industry Growth Program (IGP) providing commercialization pathway support, funded by Department of Industry, Science and Resources. Successfully completed 2025 program.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Support through MedTech Accelerator cohort and participation in RESI JPM Week activities, strengthening Queensland's MedTech ecosystem presence.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision psychiatry company using biomarker-driven patient stratification to develop depression and other CNS therapeutics. Closest strategic peer, employing a similar biomarker-and-AI strategy to address heterogeneity in depression, although Alto focuses on stratification for drug development rather than a predictive diagnostic test.

TypeBroad incumbent
Description

Major clinical laboratory services provider with broad women's health and mental health testing menus. Comparable as a potential distribution and commercial partner for the PPD test, given its nationwide clinical lab infrastructure and existing payer relationships.

3Mindstrong (historical)
TypeEmerging player
Description

Digital biomarker company that used smartphone behavioral data and AI to detect and monitor mental health conditions. Comparable as an early-stage precision psychiatry company applying objective, data-driven biomarkers to mental health, though Mindstrong focused on digital rather than molecular biomarkers.

TypeBroad incumbent
Description

Large clinical laboratory network with extensive maternal and women's health diagnostics, including NIPT and hormone testing. Comparable as a potential commercial partner for distribution and reimbursement of a novel blood-based PPD diagnostic.

TypeOthers
Description

Protein biomarker discovery platform using SomaScan technology for high-throughput proteomics. Functions as an enabler/platform for protein biomarker discovery analogous to Olink, supporting similar downstream diagnostic applications in multiple therapeutic areas.

TypeOthers
Description

Leading proteomics platform provider (now part of Thermo Fisher) whose Olink technology Ketim uses for biomarker discovery. Comparable as a proteomics platform enabler, though Olink is a tools/technology provider rather than a downstream diagnostics developer.

TypeEmerging player
Description

Digital maternal health platform providing postpartum support, screening, and care navigation. Comparable as a maternal mental health company addressing the same end population (pregnant and postpartum mothers), though it focuses on care delivery rather than biomarker-based diagnostics.

TypeBroad incumbent
Description

Established molecular diagnostics company with a portfolio of genetic and biomarker tests across women's health, oncology, and mental health. Comparable as a large diagnostic player that could enter or replicate the PPD biomarker space, and a potential acquirer or partner for Ketim's pipeline.

TypeEmerging player
Description

Clinical-stage biotechnology company developing treatments for CNS and infectious diseases, with a growing emphasis on biomarker-driven approaches in mental health. Comparable in applying biomarker/AI strategies to psychiatric drug development, though it is focused on therapeutics rather than diagnostics.

TypeBroad incumbent
Description

Commercial-stage biopharmaceutical company with Zurzuvae, the first FDA-approved oral therapy specifically for postpartum depression. Operates in the same PPD indication and validates clinical and commercial demand for PPD-focused innovation, though Sage is a drug developer rather than a diagnostics company.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ketim Therapeutics Pty Ltd

Maternal Mental Health Diagnosticsketim.com.au

Ketim Therapeutics (Ketim Technologies) is a Brisbane, Australia-based biotechnology company developing the world's first protein blood-based predictive test for postpartum depression, paired with an AI/ML-enabled multimodal biomarker database for maternal mental-health diagnostics and pharmaceutical drug-discovery applications.

What Ketim Therapeutics Pty Ltd does

Ketim Therapeutics Pty Ltd (doing business as Ketim Technologies) is an Australian, Brisbane-based biotechnology company founded in 2024 that is developing what it claims to be the world's first protein blood-based objective clinical test for postpartum depression (PPD). The core product is a predictive blood assay built on a proprietary four-protein biomarker signature reported to deliver up to 94% sensitivity and specificity (AUC) when performed at 24 weeks gestation — before symptoms manifest — derived from screening over 5,400 candidate proteins against multimodal patient data. The assay is paired with an AI/ML-enabled analytical pipeline and a proprietary database integrating biomarker, clinical, and patient-reported data, intended to support biomarker discovery, drug discovery, and clinical-trial optimization for psychiatric conditions more broadly. The company has filed an international PCT patent application covering the biomarker technology (Feb 2026) and is generating validation data through strategic partnerships with Mater Research (Queensland Family Cohort), the Australian Genome Research Facility (proteomics via Olink platforms), the Thompson Institute at the University of the Sunshine Coast, and provisional access to the ORIGINS Birth Cohort Biobank. A Swedish dried-blood-spot partnership with Capitainer extends sample-collection flexibility for the test.

The company is pre-revenue and pre-commercialization: no pricing is publicly disclosed, the product is not yet approved by the FDA, TGA, or equivalent regulators, and the trials.ketim.com.au portal exists to enroll validation cohorts rather than to deliver paid services. Planned revenue streams include clinical laboratory testing services and potential kit sales for the blood-based diagnostic, biomarker database licensing to pharmaceutical companies, and biomarker-driven clinical trial optimization services. Planned customer segments are healthcare providers and pregnant women for the diagnostic test, and pharmaceutical companies for the database and trial-optimization offerings. As of late 2025 / early 2026 the company had closed an oversubscribed AUD $1.2 million pre-seed round at a $3.7 million post-money valuation, accumulated roughly AUD $1.275 million in combined equity and non-dilutive grant funding (including a AUD $75K Advance Queensland Ignite Spark Grant), and was pursuing competitive grants reportedly aggregating to AUD $4.5 million for biomarker validation and regulatory progression. Go-to-market is enterprise/clinical field-sales led: direct engagement with clinicians, partnerships with maternity hospitals for cohort and biobank access, participation in accelerator programs (BEDA MedTech Global Accelerator, AusBiotech IGP), and investor and life-sciences conference presence (RESI JPM 2026, AusMedTech 2025). The operating geography is anchored in Australia with explicit strategic interest in Singapore/Southeast Asia and the United States.

Ketim Therapeutics Pty Ltd firmographics

Firmographics
Name
Ketim Therapeutics Pty Ltd
Legal name
Ketim Therapeutics Pty Ltd
Website
https://ketim.com.au
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Ketim Therapeutics (Ketim Technologies) is a Brisbane, Australia-based biotechnology company developing the world's first protein blood-based predictive test for postpartum depression, paired with an AI/ML-enabled multimodal biomarker database for maternal mental-health diagnostics and pharmaceutical drug-discovery applications.
Ownership category
akta.pro rank

Ketim Therapeutics Pty Ltd industry classification

Industry
Product category
Maternal Mental Health Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (6215)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Biomarker diagnostics
  • Postpartum depression screening
  • Precision psychiatry
  • Blood-based biomarker testing
  • Maternal mental health

Where Ketim Therapeutics Pty Ltd is headquartered

Location

Headquarters

HQ city
Brisbane
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Ketim Therapeutics Pty Ltd business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Blood-Based Diagnostic Test Sales: The company is developing and plans to commercialize a protein blood-based diagnostic test for postpartum depression prediction, expected to generate revenue through clinical laboratory testing services and potentially kit sales.
  2. Biomarker Database Licensing: Licensing of proprietary biomarker database to pharmaceutical companies for drug discovery and development purposes.
  3. Clinical Trial Optimization Services: Providing biomarker-driven insights to pharmaceutical companies for clinical trial design and patient stratification.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Ketim Therapeutics Pty Ltd product offering

Product offering

Core offering

Ketim Technologies is commercializing a proprietary protein blood-based diagnostic test that predicts postpartum depression risk at 24 weeks gestation using a four-protein biomarker signature with up to 94% sensitivity and specificity (AUC), before symptoms occur. The company is also building an AI/ML-enabled proprietary multimodal database that integrates biomarker, clinical, and health data to support biomarker discovery, drug discovery, and clinical trial optimization for perinatal mental health.

Product overview

Ketim Technologies is developing the world's first protein blood-based objective clinical test for postpartum depression (PPD) using a proprietary four-protein biomarker signature achieving up to 94% sensitivity and specificity. The core offering consists of a predictive blood test that can identify PPD risk at 24 weeks gestation, before symptoms manifest. This is supported by an AI-driven proprietary database that integrates multimodal patient data (molecular, clinical, and health information) to power biomarker discovery and drug discovery for mental health conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Postpartum Depression (PPD) Blood Test A novel protein blood-based objective clinical test that predicts postpartum depression (PPD) risk using a proprietary four-protein biomarker signature with up to 94% sensitivity and specificity (AUC), performed at 24 weeks gestation—months before symptoms occur. Intended for healthcare providers, obstetricians, and antenatal care clinics to enable early screening and personalized intervention for pregnant women.
  • AI-Driven Proprietary Biomarker and Drug Discovery Database A proprietary biomarker and drug discovery database that integrates multimodal patient data including molecular, clinical, and health information, powered by advanced AI and machine learning. Designed to uncover novel biomarkers, accelerate drug development, and optimize clinical trial design for pharmaceutical and biotech partners in mental health (starting with PPD).

Quantifiable outcome

  • 94% sensitivity and specificity (AUC) for PPD prediction at 24 weeks gestation
  • +2 more outcomes

Companies that use Ketim Therapeutics Pty Ltd

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles4 records

Ketim Therapeutics Pty Ltd technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Ketim Therapeutics Pty Ltd partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Mater ResearchcoreStrategic or Co-development PartnerStrategic partnership leveraging the Queensland Family Cohort (QFC) study for predictive biomarker research for perinatal depression. The collaboration provides access to longitudinal datasets encompassing genetic, environmental, and health factors for biomarker discovery.
  • Australian Genome Research Facility (AGRF) LtdcoreStrategic or Co-development PartnerOngoing collaboration advancing biomarker discovery and translational pipeline. AGRF provides proteomics expertise and genomic technologies supporting Ketim's biomarker validation work using Olink proteomics platforms.
  • Thompson Institute at University of the Sunshine CoastcoreStrategic or Co-development PartnerResearch collaboration to evaluate the specificity of Ketim's postpartum depression biomarker signature through independent validation studies.
  • The Kids Research Institute (ORIGINS Birth Cohort Biobank)coreStrategic or Co-development PartnerProvisional approval to access the ORIGINS Birth Cohort Biobank for independent validation of postpartum depression biomarker panel. Enables validation studies in an independent birth cohort.
  • Brisbane Economic Development Agency MedTech Global AcceleratorminorChannel Partner/ Reseller/ DistributorSelected for Year 4 Cohort of BEDA's MedTech Global Accelerator Program supporting global expansion strategy and commercialization pathways.
  • AusBiotech (Industry Growth Program)coreStrategic or Co-development PartnerAusBiotech-delivered Industry Growth Program (IGP) providing commercialization pathway support, funded by Department of Industry, Science and Resources. Successfully completed 2025 program.
  • Brisbane Economic Development AgencyminorGTM or Marketing PartnerSupport through MedTech Accelerator cohort and participation in RESI JPM Week activities, strengthening Queensland's MedTech ecosystem presence.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Ketim Therapeutics Pty Ltd competitors and assessment

Company assessment

Direct peers

  • Alto Neuroscience: Clinical-stage precision psychiatry company using biomarker-driven patient stratification to develop depression and other CNS therapeutics. Closest strategic peer, employing a similar biomarker-and-AI strategy to address heterogeneity in depression, although Alto focuses on stratification for drug development rather than a predictive diagnostic test.

Broad incumbents

  • Quest Diagnostics: Major clinical laboratory services provider with broad women's health and mental health testing menus. Comparable as a potential distribution and commercial partner for the PPD test, given its nationwide clinical lab infrastructure and existing payer relationships.
  • Labcorp (Laboratory Corporation of America): Large clinical laboratory network with extensive maternal and women's health diagnostics, including NIPT and hormone testing. Comparable as a potential commercial partner for distribution and reimbursement of a novel blood-based PPD diagnostic.
  • Myriad Genetics: Established molecular diagnostics company with a portfolio of genetic and biomarker tests across women's health, oncology, and mental health. Comparable as a large diagnostic player that could enter or replicate the PPD biomarker space, and a potential acquirer or partner for Ketim's pipeline.
  • Sage Therapeutics: Commercial-stage biopharmaceutical company with Zurzuvae, the first FDA-approved oral therapy specifically for postpartum depression. Operates in the same PPD indication and validates clinical and commercial demand for PPD-focused innovation, though Sage is a drug developer rather than a diagnostics company.

Emerging players

  • Mindstrong (historical): Digital biomarker company that used smartphone behavioral data and AI to detect and monitor mental health conditions. Comparable as an early-stage precision psychiatry company applying objective, data-driven biomarkers to mental health, though Mindstrong focused on digital rather than molecular biomarkers.
  • Mahmee: Digital maternal health platform providing postpartum support, screening, and care navigation. Comparable as a maternal mental health company addressing the same end population (pregnant and postpartum mothers), though it focuses on care delivery rather than biomarker-based diagnostics.
  • Brii Biosciences: Clinical-stage biotechnology company developing treatments for CNS and infectious diseases, with a growing emphasis on biomarker-driven approaches in mental health. Comparable in applying biomarker/AI strategies to psychiatric drug development, though it is focused on therapeutics rather than diagnostics.

Others

  • SomaLogic: Protein biomarker discovery platform using SomaScan technology for high-throughput proteomics. Functions as an enabler/platform for protein biomarker discovery analogous to Olink, supporting similar downstream diagnostic applications in multiple therapeutic areas.
  • Olink (Thermo Fisher Scientific): Leading proteomics platform provider (now part of Thermo Fisher) whose Olink technology Ketim uses for biomarker discovery. Comparable as a proteomics platform enabler, though Olink is a tools/technology provider rather than a downstream diagnostics developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Ketim Therapeutics Pty Ltd social profiles

Digital presence

Ketim Therapeutics Pty Ltd financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ketim Therapeutics Pty Ltd leadership team

Management profile

Number of profiles

Profiles6 records

Ketim Therapeutics Pty Ltd funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ketim Therapeutics Pty Ltd M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ketim Therapeutics Pty Ltd

What does Ketim Therapeutics Pty Ltd do?

Ketim Technologies is commercializing a proprietary protein blood-based diagnostic test that predicts postpartum depression risk at 24 weeks gestation using a four-protein biomarker signature with up to 94% sensitivity and specificity (AUC), before symptoms occur. The company is also building an AI/ML-enabled proprietary multimodal database that integrates biomarker, clinical, and health data to support biomarker discovery, drug discovery, and clinical trial optimization for perinatal mental health.

Is Ketim Therapeutics Pty Ltd a public or private company?

Ketim Therapeutics Pty Ltd is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ketim Therapeutics Pty Ltd founded?

Ketim Therapeutics Pty Ltd was founded in 2024. It employs 1 to 10 people.

Where is Ketim Therapeutics Pty Ltd based?

Ketim Therapeutics Pty Ltd is headquartered in Brisbane, Australia, in the Oceania region.

How does Ketim Therapeutics Pty Ltd make money?

Three revenue lines are on record. Blood-Based Diagnostic Test Sales are the primary driver. The others are biomarker Database Licensing and clinical Trial Optimization Services.

Who are Ketim Therapeutics Pty Ltd's main competitors?

Alto Neuroscience is listed as a direct peer. Broad incumbents are Quest Diagnostics, Labcorp (Laboratory Corporation of America), Myriad Genetics and Sage Therapeutics. Emerging players are Mindstrong (historical), Mahmee and Brii Biosciences. Others are SomaLogic and Olink (Thermo Fisher Scientific).

Does Ketim Therapeutics Pty Ltd have an API?

No public API is recorded for Ketim Therapeutics Pty Ltd.

What industry is Ketim Therapeutics Pty Ltd in?

Ketim Therapeutics Pty Ltd's product category is Maternal Mental Health Diagnostics. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales